Clinical Trial Update: Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the combination of Interleukin-2 with sorafenib for unresectable or metastatic clear cell renal cell carcinoma and metastatic melanoma;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Melanoma

Drugs mentioned

• Interleukin-2 (interleukin-2)
• Sorafenib (Sorafenib)

Snippet

Sponsor: Ohio State University Comprehensive Cancer Center | Conditions: Renal Cancer, Melanoma | Phase 1 | Status: COMPLETED